[7] Gordon MJ, et al. Cancer. 2024 Mar 15;130(6):876-885. [8] Yu H et al., Mol Ther Oncolytics. 2021 Apr 3:21:158-170. [9] Xu JD,et al. Blood (2023) 142 (Supplement 1): 6146 审校:Cherry 排版:Red ...
MZL的疾病发展呈现惰性,患者生存期较长。MZL的发病机制、临床表现和治疗应答具有异质性,不同亚型患者采取的治疗策略不同。目前MZL的治疗方案包括手术、放疗、化疗和靶向治疗等[2]。近年来布鲁顿酪氨酸激酶抑制剂(BTKi)等小分子靶向药物的研发与应用,为MZL...
参考文献 1. 中国淋巴瘤治疗指南(2022年版) 2. Xia C, et al. Cancer statistics in China and United States, 2022 profiles, trends, and determinants. Chin Med J (Engl). 2022 Feb 9 3. 张轶文, 等. 脾和淋巴结边缘区惰性淋巴瘤生物学特征及治疗研究进展[J]. 白血病.淋巴瘤, 2018, 27(4):6 ...
[3] Allemani C,et al. CONCORD Working Group. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37513025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018 Mar 17;391(10125):1023-...
Background: QOL can be affected by disease burden, side effects of treatment, and psychosocial effects of living with cancer. Although MZL is considered incurable, we previously found that patients diagnosed from 2002-2015 had a good QOL both at baseline (BL) and the first decade after ...
[3] Opat S, Tedeschi A, Linton K, et al. The MAGNOLIA Trial: Zanubrutinib, a next-generation bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed/refractory marginal zone lymphoma. Clin Cancer Res. Published online September 15, 2021. doi: 10.1158/1078-0432. CCR-21...
[3] Opat S, Tedeschi A, Linton K, et al. The MAGNOLIA Trial: Zanubrutinib, a next-generation bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed/refractory marginal zone lymphoma. Clin Cancer Res . Published online September 15, 2021 . doi: 10.1158/1078-0432. ...
[4] National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Leukemia —Chronic Lymphocytic Leukemia (CLL). Accessed December, 2022. https://seer.cancer.gov/statfacts/html/clyl.html [5] American Cancer Society. What is chronic lymphocytic leukemia? Updated...
(n=2); myocardial infarction in a patient with preexisting cardiovascular disease (n=1); acute myeloid leukemia in a patient with prior exposure to an alkylating agent (n=1); septic encephalopathy following radical cystectomy and ileal conduit in a patient with recurrent bladder cancer (n...
IsaacsonP,WrightDH.Cancer1983 chronicAgstimulation-chronicinflammation INFECTIONAUTO-ANTIGEN Epitheliumof extranodalsites Microenvironnement Specific treatment Ag-dependant AcquisitionofMALTMALTlymphoma Ag-independant ThieblemontC.etal,PonzoniM.SeminCancerBiol.2014MALTlymphoma ...